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INTRODUCTION {#sec1-1}
============

Postoperative delirium (POD) occurs between 24 and 72 h after any surgery and can persist for months.\[[@ref15],[@ref16]\] The reported incidence of POD specifically following spine surgery ranges from 3.3% to 3.8%.\[[@ref4],[@ref8]\]

Desflurane and isoflurane are two commonly used inhalational anesthetic agents. While animal studies have shown prolonged exposure to isoflurane may be neurotoxic, clinical series have reported faster emergence and less postoperative cognitive dysfunction (POCD) utilizing desflurane.\[[@ref2],[@ref11],[@ref12],[@ref14],[@ref17]\] Here, in a prospective, randomized double-blind clinical trial involving 60 patients undergoing spine surgery, we compared the incidence of POD at 24 (day 1) and 72 h (day 3) utilizing isoflurane versus desflurane. We also evaluated whether various other perioperative factors differentially influenced the incidence of POD utilizing these two anesthetics.

MATERIALS AND METHODS {#sec1-2}
=====================

A prospective randomized double-blind clinical trial was conducted (2016--2017) in 60 patients, ages 18--65 years old, scheduled to undergo spine surgery; they provided written informed consent \[[Figure 1](#F1){ref-type="fig"}\]. They were randomly divided into two equal groups; Group I (Isoflurane; *n* = 30) and Group D (Desflurane; *n* = 30) utilizing computer-generated random numbers. There were multiple exclusion criteria \[[Figure 1](#F1){ref-type="fig"}\]. Further, both the patients and the investigators assessing for POD were blinded to the allocation groups.
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Anesthetic technique {#sec2-2_1}
--------------------

Patients were screened for cognitive dysfunction preoperatively using the Mini-Cog Test.\[[@ref1]\] All patients were monitored intraoperatively with five lead electrocardiogram, pulse oximetry, and non-invasive blood pressure assessment. Anesthesia was induced with intravenous (IV) propofol (2--2.5 mg/kg) and fentanyl (2 µg/kg) followed by vecuronium (0.1 mg/kg) (e.g., for endotracheal intubation). Anesthesia was maintained with either isoflurane or desflurane. Fentanyl infusion (0.5--2 µg/kg/h) and intermittent doses of vecuronium (0.06 mg/kg) were administered intraoperatively. State entropy was maintained at 40--60 for adequate depth of anesthesia. After completion of surgery, neuromuscular blockade was reversed with IV neostigmine 0.05 mg/kg and glycopyrrolate 0.01 mg/kg.

Postoperative assessment of POD {#sec2-2_2}
-------------------------------

The diagnosis and severity of POD utilized the 3D-Confusion Assessment Method (CAM) and CAM-severity (CAM-S) long-form delirium severity score, respectively, on postoperative days 1 and 3.\[[@ref6],[@ref13]\]

Statistical analysis {#sec2-2_3}
--------------------

The results of a previously conducted study on POCD comparing isoflurane and desflurane were used to calculate the sample size in our study to prove the superiority of desflurane over isoflurane with a margin of at least 5% using an alpha error of 0.05 and power of 85%.\[[@ref17]\] The estimated sample size was 60 with 30 in each arm. All statistical analysis was done using SPSS version 22 (SPSS Inc., Chicago, IL, version 16.0 for Windows).

RESULTS {#sec1-3}
=======

POD results {#sec2-3_1}
-----------

There were no statistically significant differences utilizing isoflurane versus desflurane on the incidence of POD between the two groups on postoperative days 1 (10% vs. 13.3%) and 3 (6.6% vs. 0%), respectively \[[Tables 1](#T1){ref-type="table"}-[3](#T3){ref-type="table"}\]. There were also similar CAM-S delirium severity scores for isoflurane versus desflurane groups on postoperative days 1 (1.5 vs. 1) and 3 (0.5 vs. 0.5), respectively. Further, the respective postoperative pain scores on day 1 and day 3 were comparable. The median ages of those who tested positive for delirium were also similar; 36 years for postoperative day 1 and 35.5 years for postoperative day 3. A univariable and multivariable analysis was performed to look for the association of the various perioperative factors with POD on day 1 and day 3; there were none (*P* \> 0.05) \[[Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\].

###### 

Demographic and clinical characteristics.
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###### 

Intraoperative anesthetic and surgical variables.
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###### 

Outcome data: Postoperative delirium.
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DISCUSSION {#sec1-4}
==========

Comparable outcomes for POD with isoflurane versus desflurane {#sec2-4_1}
-------------------------------------------------------------

Our original hypothesis was that isoflurane may be associated with an increased incidence of POD versus desflurane in patients undergoing spinal surgery. We found the incidence and severity of POD in middle-aged adults undergoing spine surgery were similar on postoperative days 1 and 3.

Animal studies {#sec2-4_2}
--------------

Animal studies have demonstrated different incidences of neurotoxicity utilizing isoflurane and desflurane as inhalational anesthetics; some studies showed isoflurane to be neurotoxic, while others demonstrated both isoflurane and desflurane were neuroprotective.\[[@ref2],[@ref3],[@ref10]-[@ref12]\] In neonatal mice, Kodama *et al*. demonstrated that desflurane was more neurotoxic than sevoflurane and isoflurane.\[[@ref9]\] Alternatively, in newborn mice, Istaphanous *et al*. showed that equipotent doses of isoflurane, sevoflurane, and desflurane were equally neurotoxic.\[[@ref7]\]

Prior incidence of POD in patients undergoing spine surgery {#sec2-4_3}
-----------------------------------------------------------

Previous studies on POD following spine surgery showed a higher incidence of delirium in patients older than 60 years.\[[@ref4],[@ref8]\] In the studies by Gao *et al*. and Kawaguchi *et al*., the incidence of POD was 3.3% and 3.8%, respectively.\[[@ref4],[@ref8]\] However, Kawaguchi *et al*. found that all patients who tested positive for delirium were older than 70 years of age (POD incidence of 12.5% in \>70 years). A prior study in our hospital showed that delirium was diagnosed in 53% of patients 16--45 years of age, 24% who were between 46 and 60 years of age, but in only 19% of patients \>60 years of age.\[[@ref5]\] Here, we found a comparable overall incidence of POD utilizing isoflurane versus desflurane on postoperative days 1 (11.7%) and 3 (3.3%). Further, the median age of those who tested positive for delirium in our study was 36 years for postoperative day 1 and 35.5 years for postoperative day 3. We also found no significant relationship between POD and other perioperative factors studied.

Limitations {#sec2-4_4}
-----------

The study included only 60 patients randomized to two different anesthetic groups, and the study was only continued for 3 postoperative days. Further, the baseline incidence of preoperative cognitive dysfunction was higher in the isoflurane (*n* = 7) versus desflurane groups (*n* = 1).

CONCLUSION {#sec1-5}
==========

The incidence and severity of POD in middle-aged patients receiving either isoflurane or desflurane for spine surgery were similar on postoperative days 1 and 3.
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